Leah E. Cowen

Dr. Leah E. Cowen


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2020 in Chemical Reviews
Verified
Journal Article
Closed access
YLYunjin Lee
Yunjin Lee
EPEmily Puumala
Emily Puumala
NRNicole Robbins
Nicole Robbins
LCLeah E. Cowen
Leah E. Cowen

30 September 2005 in Science
Verified
Journal Article
Closed access
PDF file
LCLeah E. Cowen
Leah E. Cowen
SLSusan Lindquist
Susan Lindquist
Hsp90 is a molecular chaperone for many signal transducers and may influence evolution by releasing previously silent genetic variation in response to environmental change. In fungi separated by ∼800 million years of evolution, Hsp90 potentiated the evolution of drug resistance in a different way, by enabling new mutations to have immediate phenotypic consequences. Resistance was abrogated by Hsp90 inhibitors and by febrile temperatures, suggesting new therapeutic strategies and a clinical benefit of fever. During selection in a human host, drug resistance that was initially Hsp90-dependent evolved toward independence. Thus, Hsp90 can act in diverse ways to couple environmental contingency to the emergence and fixation of new traits.

10 November 2014 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
LCLeah E. Cowen
Leah E. Cowen
Dominique SanglardDominique Sanglard
Dominique Sanglard
SHSusan J. Howard
Susan J. Howard
PRP. David Rogers
P. David Rogers
David PerlinDavid Perlin
David Perlin
Antifungal therapy is a central component of patient management for acute and chronic mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal drug classes. Clinical management of fungal diseases is further compromised by the emergence of antifungal drug resistance, which eliminates available drug classes as treatment options. Once considered a rare occurrence, antifungal drug resistance is on the rise in many high-risk medical centers. Most concerning is the evolution of multidrug- resistant organisms refractory to several different classes of antifungal agents, especially among common Candida species. The mechanisms responsible are mostly shared by both resistant strains displaying inherently reduced susceptibility and those acquiring resistance during therapy. The molecular mechanisms include altered drug affinity and target abundance, reduced intracellular drug levels caused by efflux pumps, and formation of biofilms. New insights into genetic factors regulating these mechanisms, as well as cellular factors important for stress adaptation, provide a foundation to better understand the emergence of antifungal drug resistance.

30 June 2020 in mBio
Verified
Journal Article
Open access
PDF file
MFMatthew C. Fisher
Matthew C. Fisher
SGSarah J. Gurr
Sarah J. Gurr
Christina CuomoChristina Cuomo
Christina Cuomo
DBDavid S. Blehert
David S. Blehert
HJHailing Jin
Hailing Jin
LCLeah E. Cowen
Leah E. Cowen
The fungal kingdom includes at least 6 million eukaryotic species and is remarkable with respect to its profound impact on global health, biodiversity, ecology, agriculture, manufacturing, and biomedical research. Approximately 625 fungal species have been reported to infect vertebrates, 200 of which can be human associated, either as commensals and members of our microbiome or as pathogens that cause infectious diseases. These organisms pose a growing threat to human health with the global increase in the incidence of invasive fungal infections, prevalence of fungal allergy, and the evolution of fungal pathogens resistant to some or all current classes of antifungals.

1 June 2011 in Microbiology and Molecular Biology Reviews
Verified
Journal Article
Open access
RSRebecca Shapiro
Rebecca Shapiro
NRNicole Robbins
Nicole Robbins
LCLeah E. Cowen
Leah E. Cowen
SUMMARY: Pathogenic fungi have become a leading cause of human mortality due to the increasing frequency of fungal infections in immunocompromised populations and the limited armamentarium of clinically useful antifungal drugs.Candida albicans,Cryptococcus neoformans, andAspergillus fumigatusare the leading causes of opportunistic fungal infections. In these diverse pathogenic fungi, complex signal transduction cascades are critical for sensing environmental changes and mediating appropriate cellular responses. ForC. albicans, several environmental cues regulate a morphogenetic switch from yeast to filamentous growth, a reversible transition important for virulence. Many of the signaling cascades regulating morphogenesis are also required for cells to adapt and survive the cellular stresses imposed by antifungal drugs. Many of these signaling networks are conserved inC. neoformansandA. fumigatus, which undergo distinct morphogenetic programs during specific phases of their life cycles. Furthermore, the key mechanisms of fungal drug resistance, including alterations of the drug target, overexpression of drug efflux transporters, and alteration of cellular stress responses, are conserved between these species. This review focuses on the circuitry regulating fungal morphogenesis and drug resistance and the impact of these pathways on virulence. Although the three human-pathogenic fungi highlighted in this review are those most frequently encountered in the clinic, they represent a minute fraction of fungal diversity. Exploration of the conservation and divergence of core signal transduction pathways acrossC. albicans,C. neoformans, andA. fumigatusprovides a foundation for the study of a broader diversity of pathogenic fungi and a platform for the development of new therapeutic strategies for fungal disease.

1 October 2018 in Current Opinion in Microbiology
Verified
Journal Article
Closed access
NRNicole M Revie
Nicole M Revie
KIKali R Iyer
Kali R Iyer
NRNicole Robbins
Nicole Robbins
LCLeah E. Cowen
Leah E. Cowen